CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

Regeneron's co-founder, Dr. George D. Yancopoulos, who is also the company's president and chief scientific officer, described the 23andMe acquisition as part of Regeneron's strategy to use DNA to ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s ...

Regeneron Pharmaceuticals just scooped up 23andMe and its treasure trove of 15 million customer DNA profiles for a bargain basement $256 million – which works out to roughly $2.56 per genetic ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from ...

Through the deal, Regeneron aims to bolster its capabilities in genomics-driven drug discovery by integrating 23andMe's trove of over 15 million customer DNA profiles, collected via its popular ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies insisted the sensitive genetic data provided to 23andMe by 15 million ...

Regeneron Pharmaceuticals on Monday announced it is buying 23andMe out of bankruptcy for $256 million – taking with it the company’s extensive trove of genetic samples and data.

Regeneron is trying to buy 23andMe – and by extension, your DNA information | Opinion As 23andMe’s sale proceeds, the public must remain vigilant.

Regeneron intended, he added, "to help 23andMe deliver and build upon its mission to help those interested in learning about their own DNA and how to improve their personal health, while ...